Clinical features of the group 1 patient cohort
| Clinical parameter . | Frequency . | 2-y OS . | Log-rank . |
|---|---|---|---|
| Sex | |||
| M/F ratio | 1.1:1 | ||
| Age (y) | |||
| Median (range) | 66 (11-90) | ||
| No more than 60 | 71 | 65% | |
| More than 60 | 106 | 43% | P = .0001 |
| Ann Arbor stage | |||
| I | 48 (27%) | ||
| II | 39 (22%) | 68% (I-II) | |
| III | 52 (29%) | ||
| IV | 38 (22%) | 38% (III-IV) | P = .0001 |
| No. of extranodal sites | |||
| 0 to 1 | 164 | 55% | |
| At least 2 | 11 | 65% | NS |
| N/A | 2* | ||
| LDH | |||
| Normal | 80 | 69% | |
| High | 53 | 26% | P< .0001 |
| N/A | 44* | ||
| Performance status | |||
| 0 to 1 | 133 | 60% | |
| At least 2 | 44 | 32% | P = .0004 |
| IPI group† | |||
| Low (0-1) | 67 (42%) | 78% | |
| Low-intermediate (2) | 38 (24%) | 54% | |
| High-intermediate (3) | 26 (16%) | 22% | |
| High (4-5) | 12 (8%) | 8% | P< .0001 |
| Unclassifiable (no LDH) | |||
| 1 or 2 | 11 | ||
| 2 or 3 | 16 (10%)* | ||
| 3 or 4 | 7 |
| Clinical parameter . | Frequency . | 2-y OS . | Log-rank . |
|---|---|---|---|
| Sex | |||
| M/F ratio | 1.1:1 | ||
| Age (y) | |||
| Median (range) | 66 (11-90) | ||
| No more than 60 | 71 | 65% | |
| More than 60 | 106 | 43% | P = .0001 |
| Ann Arbor stage | |||
| I | 48 (27%) | ||
| II | 39 (22%) | 68% (I-II) | |
| III | 52 (29%) | ||
| IV | 38 (22%) | 38% (III-IV) | P = .0001 |
| No. of extranodal sites | |||
| 0 to 1 | 164 | 55% | |
| At least 2 | 11 | 65% | NS |
| N/A | 2* | ||
| LDH | |||
| Normal | 80 | 69% | |
| High | 53 | 26% | P< .0001 |
| N/A | 44* | ||
| Performance status | |||
| 0 to 1 | 133 | 60% | |
| At least 2 | 44 | 32% | P = .0004 |
| IPI group† | |||
| Low (0-1) | 67 (42%) | 78% | |
| Low-intermediate (2) | 38 (24%) | 54% | |
| High-intermediate (3) | 26 (16%) | 22% | |
| High (4-5) | 12 (8%) | 8% | P< .0001 |
| Unclassifiable (no LDH) | |||
| 1 or 2 | 11 | ||
| 2 or 3 | 16 (10%)* | ||
| 3 or 4 | 7 |
Components of the IPI were unavailable (N/A) in a number of patients. In 44 cases LDH at presentation was not recorded. Of these, the IPI could not be determined in 34 cases; however, in 15 cases an extra score (in the event of the LDH being greater than normal) would have resulted in a reclassification from 2 to 3; therefore, these patients were classified in the intermediate IPI group. In the remaining 11 of 44 cases lacking LDH data, the score was either 0 to 1 or 4 to 5 and the IPI classification was not affected. Similarly, 2 cases lacked details of extranodal involvement; in one case the IPI score was either 2 or 3 and in the other case the score was 4 or 5.
In the IPI categories, percentages are calculated using the number of cases with a classifiable IPI group (159) as the denominator.